Annamycin 是一种具有抗肿瘤活性的蒽环类抗生素,可与拓扑异构酶 II 相互作用,诱导 DNA 双链断裂、触发细胞死亡并发挥细胞毒素作用,在小鼠中可抑制晚期皮下黑色素瘤和皮下鳞状细胞癌的生长、延长皮下网状肉瘤小鼠及肺癌肺转移模型的生存期,可用于黑色素瘤、网状细胞肉瘤、肺癌、非小细胞肺癌和小细胞肺癌的相关研究。
产品编号: MS-C24995 CAS No.: 92689-49-1 分子式: C26H25IO11 分子量: 640.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Annamycin 是一种具有抗肿瘤活性的蒽环类抗生素,可与拓扑异构酶 II 相互作用,诱导 DNA 双链断裂、触发细胞死亡并发挥细胞毒素作用,在小鼠中可抑制晚期皮下黑色素瘤和皮下鳞状细胞癌的生长、延长皮下网状肉瘤小鼠及肺癌肺转移模型的生存期,可用于黑色素瘤、网状细胞肉瘤、肺癌、非小细胞肺癌和小细胞肺癌的相关研究。

生物实验数据

生物活性 Annamycin is an anthracycline antibiotic with antitumor activity that interacts with topoisomerase II to induce DNA double-strand breaks, trigger cell death, and exert cytotoxic effects; in mice, it inhibits the growth of advanced subcutaneous melanoma and subcutaneous squamous cell carcinoma and prolongs survival in mice with subcutaneous reticulosarcoma and in lung cancer lung metastasis models, and it can be used for research related to melanoma, reticulosarcoma, lung cancer, non-small cell lung cancer, and small cell lung cancer.
体外研究
(In Vitro)

Annamycin (4 h-72 h) 多药耐药 KB-V1 细胞、P388/Dox 细胞、CEM/Vbl 细胞、8226/R 细胞对游离态和多层脂质体包载的 Annamycin 均表现出部分交叉耐药缺失。
Annamycin (4.3 min) 可在孵育时间为 4.3 min 时完全抑制拓扑异构酶 IIα 介导的线性化 pBR322 质粒的 DNA 切割。
Annamycin (0.1-10 μM; 1 h) 可强效抑制 P-gp 表达细胞中 P-糖蛋白介导的外排作用,其 IC50 为 0.7 μM。
Annamycin (4-72 h) 可绕开 MCF-7、MCF-7/VP、UMCC-1 和 UMCC-1/VP 细胞中 MRP 介导的多药耐药性;在 4 和 72 hr 暴露时长下,其耐药指数较低 (1.1、1.4、1.3),且 ID50 值根据细胞系和暴露时间的不同,范围为 2.10 至 8.30 μg/mL。
Annamycin (5 μg/mL; 1 hr) 在 MCF-7 细胞中诱导 DNA 双链断裂。

体内研究
(In Vivo)

Free Annamycin (5 mg/kg; i.v.; single)、Multilamellar liposomal Annamycin (5 mg/kg; i.v.; single) 及 Small unilamellar liposomal Annamycin (5 mg/kg; i.v.; single ) 均可抑制晚期皮下 B16 黑色素瘤的生长,其中小单层脂质体包载的阿那霉素 (S-Ann) 的疗效最佳,肿瘤生长抑制率 (TGI) 达 74.4 %。
Free Annamycin (4 mg/kg; i.v.; single)、Multilamellar liposomal Annamycin (4 mg/kg; i.v.; single) 和 Small unilamellar liposomal Annamycin (4 mg/kg; i.v.; single ) 可显著延长皮下接种 M5076 网状肉瘤的小鼠的生存期,其中小单层脂质体包封安那霉素 (S-Ann) 的疗效最高,达到 74.4 %ILS。
Free Annamycin (4 mg/kg; i.v.;single)、Multilamellar liposomal Annamycin (4 mg/kg; i.v.; single) 及 Small unilamellar liposomal Annamycin (4 mg/kg; i.v.; single ) 可显著延长荷 Lewis 肺癌肺转移模型小鼠的生存期;其中小单层脂质体包载的 Annamycin (S-Ann) 疗效最佳,在低接种量下实现了 85.3 %ILS,在高接种量下实现了 57.6 %ILS,且带来了最高的长期无瘤生存率。
Free Annamycin (4 mg/kg; i.v.; weekly; 3 injections)、Multilamellar liposomal Annamycin (4 mg/kg; i.v.; weekly; 3 injections) 及 Small unilamellar liposomal Annamycin (4 mg/kg; i.v.; weekly; 3 injections) 均可抑制皮下KB 鳞状细胞癌异种移植物的生长,其中小单层脂质体包载的 Annamycin (S-Ann) 疗效最高,达到 87.8 %TGI。
Free Annamycin (4 mg/kg; i.v.; weekly; 3 injections)、Multilamellar liposomal Annamycin (4 mg/kg; i.v.; weekly; 3 injections) 及 Small unilamellar liposomal Annamycin (4 mg/kg; i.v.; weekly; 3 injections) 可强效抑制皮下多药耐药 KB-V1 鳞癌异种移植物的生长,其中小单层脂质体包载的 Annamycin (S-Ann) 疗效最佳,TGI 达 92.6%,肿瘤生长速率降低 19 倍。

Animal Model: C57BL/6 (male, 7-8 weeks old, inoculated s.c. with 2×106 viable B16 melanoma cells)
Dosage: 5 mg/kg (Free Annamycin); 5 mg/kg (Multilamellar liposomal Annamycin); 5 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; single injection
Result: Produced a %TGI of 65.0 (Free Annamycin).
Produced a %TGI of 67.6 (Multilamellar liposomal Annamycin).
Produced a %TGI of 74.4 (Small unilamellar liposomal Annamycin).
Was significantly more effective than both Free Annamycin and Multilamellar liposomal Annamycin (P < 0.05, Small unilamellar liposomal Annamycin).
Animal Model: C57BL/6 (male, 7-8 weeks old, inoculated s.c. with 6×105 M5076 reticulosarcoma cells)
Dosage: 4 mg/kg (Free Annamycin); 4 mg/kg (Multilamellar liposomal Annamycin); 4 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; single injection
Result: Produced a %ILS of 45.6 (Free Annamycin).
Produced a %ILS of 63.2 (Multilamellar liposomal Annamycin).
Produced a %ILS of 74.4 (Small unilamellar liposomal Annamycin).
Was significantly more effective than doxorubicin (all Annamycin formulations).
Was significantly more effective than Multilamellar liposomal Annamycin and Free Annamycin (P < 0.01 between any two groups, Small unilamellar liposomal Annamycin).
Animal Model: C57BL/6×DBA2 F1 (B6D2F1) (male, 7 weeks old, inoculated i.v. with 3.6×105 or 1×106 Lewis lung carcinoma cells)
Dosage: 4 mg/kg (Free Annamycin); 4 mg/kg (Multilamellar liposomal Annamycin); 4 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; single injection
Result: Produced a %ILS of 39.2 with 4/10 long-term survivors (Free Annamycin, low inoculum group).
Produced a %ILS of 73.5 with 7/10 long-term survivors (Multilamellar liposomal Annamycin, low inoculum group).
Produced a %ILS of 85.3 with 8/10 long-term survivors (Small unilamellar liposomal Annamycin, low inoculum group).
Produced a %ILS of 18.7 (Free Annamycin, high inoculum group).
Produced a %ILS of 26.7 (Multilamellar liposomal Annamycin, high inoculum group).
Produced a %ILS of 57.6 (Small unilamellar liposomal Annamycin, high inoculum group).
Was significantly more effective than doxorubicin (all Annamycin formulations).
Was significantly more effective than Multilamellar liposomal Annamycin and Free Annamycin (P < 0.01 between any two groups, Small unilamellar liposomal Annamycin).
Confirmed no tumor presence in long-term survivors (autopsy).
Animal Model: nude (nu/nu) (male, 7-8 weeks old, inoculated s.c. with 0.4×106 KB squamous cell carcinoma cells)
Dosage: 4 mg/kg per injection, total 12 mg/kg (Free Annamycin); 4 mg/kg per injection, total 12 mg/kg (Multilamellar liposomal Annamycin); 4 mg/kg per injection, total 12 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; weekly; 3 injections
Result: Produced a %TGI of 78.6 (Free Annamycin).
Produced a %TGI of 83.2 (Multilamellar liposomal Annamycin).
Produced a %TGI of 87.8 (Small unilamellar liposomal Annamycin).
Was significantly more effective than Free Annamycin and doxorubicin (P < 0.05, Small unilamellar liposomal Annamycin).
Animal Model: nude (nu/nu) (male, 7-8 weeks old, inoculated s.c. with 5.8×106 KB-V1 multidrug-resistant squamous cell carcinoma cells)
Dosage: 4 mg/kg per injection, total 12 mg/kg (Free Annamycin); 4 mg/kg per injection, total 12 mg/kg (Multilamellar liposomal Annamycin); 4 mg/kg per injection, total 12 mg/kg (Small unilamellar liposomal Annamycin)
Administration: i.v.; weekly; 3 injections
Result: Produced a %TGI of 82.3 and reduced tumor growth rate 7-fold compared to controls (Free Annamycin).
Produced a %TGI of 86.4 and reduced tumor growth rate 8-fold compared to controls (Multilamellar liposomal Annamycin).
Produced a %TGI of 92.6 and reduced tumor growth rate 19-fold compared to controls (Small unilamellar liposomal Annamycin).
Was significantly more effective than doxorubicin (P < 0.01, all Annamycin formulations).
Was significantly more effective than Free Annamycin (P < 0.01) and Multilamellar liposomal Annamycin (P < 0.05, Small unilamellar liposomal Annamycin).

化学信息

分子量 640.37
分子式 C26H25IO11
CAS No. 92689-49-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础